Neurogene Inc. Stock Issued During Period, Shares, New Issues
Neurogene Inc. (NGNE) had Stock Issued During Period, Shares, New Issues of 13.51 million shares as of 2023-12-18, per its 10-K filed 2025-03-24.
Financial Statements › Shareholders' Equity
us-gaap:StockIssuedDuringPeriodSharesNewIssues · last filed 2025-03-24
- 2023-12-18: Stock Issued During Period, Shares, New Issues 13.51M shares.
- 2016-09-23: Stock Issued During Period, Shares, New Issues 6.15M shares.
- 2014-03-12: Stock Issued During Period, Shares, New Issues 4.83M shares; Stock Issued During Period, Shares, New Issues 0 month 4.83M shares.
| Period end | Stock Issued During Period, Shares, New Issues | Stock Issued During Period, Shares, New Issues 0 month |
|---|---|---|
| 2023-12-18 | 13.51M shares 10-K · filed 2025-03-24 | |
| 2016-09-23 | 6.15M shares 10-Q · filed 2016-11-09 | |
| 2014-03-12 | 4.83M shares 10-K · filed 2015-03-16 | 4.83M shares 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |